Xeris Biopharma(NASDAQ) XERS

Xeris Biopharma Holdings, Inc. makes easy-to-use injections for chronic diseases. These medicines help patients manage rare hormonal and neurological conditions. Xeris creates stable liquids that do not need mixing.

Medicines for Chronic Conditions

• Recorlev: Cortisol synthesis inhibitor for adult patients with Cushing's syndrome; generated $56.8 million in product revenue for the quarter ended June 30, 2026.
• Gvoke: Ready-to-use liquid glucagon for treating severe hypoglycemia; recorded $22.5 million in product revenue during the second quarter of 2026.
• Keveyis: Therapy for primary periodic paralysis, a rare genetic muscle disorder; accounted for $11.7 million in product revenue for the quarter ended June 30, 2026.

Strategic Moves and Partnerships

• Completed an exchange of 2025 Convertible Notes for 2028 Convertible Notes in September 2023.
• Entered an Amended and Restated Credit Agreement in March 2024 to secure $200 million in term loans.
• Executed an exchange agreement in June 2026 to settle 2028 Convertible Notes in cash.
• Collaborated with major pharmaceutical companies to apply proprietary technology to their existing drugs.

The Tech Behind the Treatment

Xeris uses specialized platforms to make stable injections without using water. These tools allow for small, ready-to-use doses that are easier for patients to use.

A Look at the Numbers

• Total revenue rose 28.7% year over year to $92.1 million in the three months ended June 30, 2026.
• Net loss was $31.1 million for the three-month period ended June 30, 2026.
• Recorlev revenue grew 80.6% year over year to $56.8 million in the second quarter of 2026.
• The company had an accumulated deficit of $700.2 million as of June 30, 2026.

From Lab to Market

Xeris has evolved from a development-stage firm into a commercial company with three main products. Its unique delivery technology supports both its own pipeline and new partnerships with other drug makers.